Carl Zeiss Meditec expands leadership position in treating glaucoma by investing in MicroOptx, Inc.
Today, Carl Zeiss Meditec announced that it has become a shareholder of MicroOptx Inc., headquartered in Minneapolis, MN. MicroOptx is a privately held company focused on innovative minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma. Their surgical technology is designed to provide effective reduction of intraocular pressure (IOP) with a simple surgical procedure.
ZEISS supports breakthrough surgical treatments for glaucoma and believes MicroOptx’s MIGS solution will complement our leading portfolio of equipment and consumables in ophthalmic surgery.
“The investment in MicroOptx will give ZEISS an early position in this new technology designed to increase MIGS adoption for treating glaucoma,” states James V. Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec.
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development.
About Carl Zeiss Meditec
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on MDAX and TecDax of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery.
With approximately 3,050 employees worldwide, the Group generated revenue of €1,280.9m in fiscal year 2017/18 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at: www.zeiss.com/med or contact:
Head of Global Communications Ophthalmic Devices Phone: +1 925 719 7825